1,233 reports of this reaction
5.0% of all ESKETAMINE HYDROCHLORIDE reports
#3 most reported adverse reaction
SUICIDAL IDEATION is the #3 most commonly reported adverse reaction for ESKETAMINE HYDROCHLORIDE, manufactured by Janssen Pharmaceuticals Inc.. There are 1,233 FDA adverse event reports linking ESKETAMINE HYDROCHLORIDE to SUICIDAL IDEATION. This represents approximately 5.0% of all 24,470 adverse event reports for this drug.
Patients taking ESKETAMINE HYDROCHLORIDE who experience suicidal ideation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SUICIDAL IDEATION is moderately reported among ESKETAMINE HYDROCHLORIDE users, representing a notable but not dominant share of adverse events.
In addition to suicidal ideation, the following adverse reactions have been reported for ESKETAMINE HYDROCHLORIDE:
The following drugs have also been linked to suicidal ideation in FDA adverse event reports:
SUICIDAL IDEATION has been reported as an adverse event in 1,233 FDA reports for ESKETAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SUICIDAL IDEATION accounts for approximately 5.0% of all adverse event reports for ESKETAMINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience suicidal ideation while taking ESKETAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.